Vogenx appoints Ken Toombs to board of directors
The clinical-stage company named the former PA Consulting chief executive as an independent director and audit committee chair, effective September 21, 2026.
SEC filing
Latest
4 stories
Tuesday, September 22
Wednesday, August 12
Vogenx registers Phase 2b trial of mizagliflozin for post-bariatric hypoglycemia
Vogenx prices $81.25 million IPO ahead of Nasdaq listing under VOGX
The clinical-stage metabolic disease company set terms for its initial public offering, with shares expected to price at $13.00 each.
SEC filing
Wednesday, July 15
Vogenx files for IPO, plans Nasdaq listing under "VOGX"
The clinical-stage metabolic disease company disclosed plans to advance its lead candidate mizagliflozin through mid-stage trials for post-bariatric hypoglycemia and gastroparesis.
SEC filing